Drugs / SON-DP
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06873659 | Feb 2025 → Apr 2027 expected | gastric cancer, liver cancer | Qurgen Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05989724 | Sep 2023 → Sep 2025 | breast cancer, colorectal cancer, malignant pancreatic neoplasm, ovarian cancer | Qurgen Inc. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-04-01 | Qurgen Inc. | Results Apr. 2026 qurgen.com ↗
In April 2026, minimal Grade 2 infusion related reactions (IRRs) were observed in all patients enrolled in the ongoing Qurgen Clinical trial with 48-hour continuous IV infusion using an infusion pump. |
| 2026-03-01 | Qurgen Inc. | Results Mar. 2026 qurgen.com ↗
Sustained tumor size reduction was observed throughout the 18-month SON-DP treatment period in some of these patients. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-01 | Qurgen Inc. | Apr. 2026 qurgen.com ↗ |
| 2026-03-01 | Qurgen Inc. | Mar. 2026 qurgen.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SON-DP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06873659 ↗ |
| Action | Restore | “The SON-DP-induced cell reprogramming also restored the mutation-caused and compromised p53 checkpoint in cancer cells” NCT06873659 ↗ |
| Modality | Protein / enzyme biologic | “SON-DP TF protein drug product” NCT05989724 ↗ |
| Route | Intravenous | “through 90-minutes IV infusion” NCT05989724 ↗ |